These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9892369)

  • 21. Patient survival on PAN/AN69 membrane hemodialysis: a ten-year analysis.
    Chandran PK; Liggett R; Kirkpatrick B
    J Am Soc Nephrol; 1993 Nov; 4(5):1199-204. PubMed ID: 8305647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dialysis membrane biocompatibility: effects on cellular elements.
    Coli L; De Sanctis LB; Feliciangeli G; Iannelli S; Scolari MP; Todeschini P; Tumietto F; Costigliola P; Chiodo F
    Nephrol Dial Transplant; 1995; 10 Suppl 10():27-32. PubMed ID: 8825429
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of cellulose diacetate and polysulfone membranes in the outcome of acute renal failure. A prospective randomized study.
    Gastaldello K; Melot C; Kahn RJ; Vanherweghem JL; Vincent JL; Tielemans C
    Nephrol Dial Transplant; 2000 Feb; 15(2):224-30. PubMed ID: 10648669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of continuous implantable renal replacement: past and future.
    Fissell WH; Fleischman AJ; Humes HD; Roy S
    Transl Res; 2007 Dec; 150(6):327-36. PubMed ID: 18022594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-flux versus low-flux haemodialysis membranes for end-stage kidney disease.
    Nephrology (Carlton); 2013 Apr; 18(4):313-4. PubMed ID: 23530531
    [No Abstract]   [Full Text] [Related]  

  • 26. The hemodialysis membranes: a historical perspective, current state and future prospect.
    Cheung AK; Leypoldt JK
    Semin Nephrol; 1997 May; 17(3):196-213. PubMed ID: 9165649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of pre-end-stage renal disease serum alkaline phosphatase for post-end-stage renal disease mortality in late-stage chronic kidney disease patients transitioning to dialysis.
    Sumida K; Molnar MZ; Potukuchi PK; Thomas F; Lu JL; Obi Y; Rhee CM; Streja E; Yamagata K; Kalantar-Zadeh K; Kovesdy CP
    Nephrol Dial Transplant; 2018 Feb; 33(2):264-273. PubMed ID: 28064159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biocompatible dialysis membranes and oxidative stress in patients wih end-stage renal disease on maintenance haemodialysis.
    Abdel-Naeem NM; Kandell NF; El-Shamaa AA; Harba TM; Abdel-Hady AA
    J Egypt Soc Parasitol; 2005 Dec; 35(3 Suppl):1173-97. PubMed ID: 16363293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dissociation between complement activation, integrin expression and neutropenia during hemodialysis.
    Rousseau Y; Carreno MP; Poignet JL; Kazatchkine MD; Haeffner-Cavaillon N
    Biomaterials; 1999 Oct; 20(20):1959-67. PubMed ID: 10514074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre-ESRD Dementia and Post-ESRD Mortality in a Large Cohort of Incident Dialysis Patients.
    Molnar MZ; Sumida K; Gaipov A; Potukuchi PK; Fülöp T; Joglekar K; Lu JL; Streja E; Kalantar-Zadeh K; Kovesdy CP
    Dement Geriatr Cogn Disord; 2017; 43(5-6):281-293. PubMed ID: 28448971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biocompatibility of cellulosic and synthetic membranes assessed by leukocyte activation.
    Hernández MR; Galán AM; Cases A; Lopez-Pedret J; Pereira A; Tonda R; Bozzo J; Escolar G; Ordinas A
    Am J Nephrol; 2004; 24(2):235-41. PubMed ID: 15031626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of dialysis dose and membrane flux in maintenance hemodialysis.
    Friedman EA
    N Engl J Med; 2003 Apr; 348(15):1491-4; author reply 1491-4. PubMed ID: 12691049
    [No Abstract]   [Full Text] [Related]  

  • 33. Renal failure in the ICU: comparison of the impact of acute renal failure and end-stage renal disease on ICU outcomes.
    Clermont G; Acker CG; Angus DC; Sirio CA; Pinsky MR; Johnson JP
    Kidney Int; 2002 Sep; 62(3):986-96. PubMed ID: 12164882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Body mass index, dialysis modality, and survival: analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II Study.
    Abbott KC; Glanton CW; Trespalacios FC; Oliver DK; Ortiz MI; Agodoa LY; Cruess DF; Kimmel PL
    Kidney Int; 2004 Feb; 65(2):597-605. PubMed ID: 14717930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship of dose of hemodialysis and cause-specific mortality.
    Bloembergen WE; Stannard DC; Port FK; Wolfe RA; Pugh JA; Jones CA; Greer JW; Golper TA; Held PJ
    Kidney Int; 1996 Aug; 50(2):557-65. PubMed ID: 8840286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of initial dialysis modality and modality switches on Medicare expenditures of end-stage renal disease patients.
    Shih YC; Guo A; Just PM; Mujais S
    Kidney Int; 2005 Jul; 68(1):319-29. PubMed ID: 15954923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient characteristics and outcomes by GN subtype in ESRD.
    O'Shaughnessy MM; Montez-Rath ME; Lafayette RA; Winkelmayer WC
    Clin J Am Soc Nephrol; 2015 Jul; 10(7):1170-8. PubMed ID: 26092830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of biocompatible dialysis membranes in acute renal failure.
    Himmelfarb J; Hakim RM
    Adv Ren Replace Ther; 1997 Apr; 4(2 Suppl 1):72-80. PubMed ID: 9113243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advances and innovations in dialysis in the 21st century.
    Power A; Duncan N; Goodlad C
    Postgrad Med J; 2009 Feb; 85(1000):102-7. PubMed ID: 19329705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States.
    Marcelli D; Stannard D; Conte F; Held PJ; Locatelli F; Port FK
    Kidney Int; 1996 Sep; 50(3):1013-8. PubMed ID: 8872978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.